MapLight Therapeutics Common Net Income
| MPLT Stock | 17.77 0.12 0.67% |
As of the 12th of February 2026, MapLight Therapeutics secures the Mean Deviation of 4.03, risk adjusted performance of 0.0496, and Downside Deviation of 4.13. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MapLight Therapeutics, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from MapLight Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting MapLight Therapeutics' valuation are summarized below:There are currently fifty-six fundamental ratios for MapLight Therapeutics that can be evaluated and compared over time across peers in the industry. All traders should check MapLight Therapeutics' last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to drop to about 789.3 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Net Loss is likely to drop to -2.26 in 2026. MapLight | Net Income | Build AI portfolio with MapLight Stock |
MapLight Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for MapLight Therapeutics is extremely important. It helps to project a fair market value of MapLight Stock properly, considering its historical fundamentals such as Net Income. Since MapLight Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MapLight Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MapLight Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will MapLight introduce new products? Factors like these will boost the valuation of MapLight Therapeutics. Expected growth trajectory for MapLight significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about MapLight Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of MapLight Therapeutics is measured differently than its book value, which is the value of MapLight that is recorded on the company's balance sheet. Investors also form their own opinion of MapLight Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is MapLight Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because MapLight Therapeutics' market value can be influenced by many factors that don't directly affect MapLight Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that MapLight Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MapLight Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MapLight Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
MapLight Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MapLight Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MapLight Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in MapLight Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding MapLight Therapeutics Common or generate 0.0% return on investment in MapLight Therapeutics over 90 days. MapLight Therapeutics is related to or competes with ProMIS Neurosciences, Edesa Biotech, Eterna Therapeutics, Biomx, BioRestorative Therapies, Immuron, and Dogwood Therapeutics. MapLight Therapeutics is entity of United States More
MapLight Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MapLight Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MapLight Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.13 | |||
| Information Ratio | 0.0341 | |||
| Maximum Drawdown | 39.27 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 8.39 |
MapLight Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MapLight Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MapLight Therapeutics' standard deviation. In reality, there are many statistical measures that can use MapLight Therapeutics historical prices to predict the future MapLight Therapeutics' volatility.| Risk Adjusted Performance | 0.0496 | |||
| Jensen Alpha | 0.1035 | |||
| Total Risk Alpha | (0.40) | |||
| Sortino Ratio | 0.0487 | |||
| Treynor Ratio | 0.144 |
MapLight Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0496 | |||
| Market Risk Adjusted Performance | 0.154 | |||
| Mean Deviation | 4.03 | |||
| Semi Deviation | 3.93 | |||
| Downside Deviation | 4.13 | |||
| Coefficient Of Variation | 1935.64 | |||
| Standard Deviation | 5.89 | |||
| Variance | 34.74 | |||
| Information Ratio | 0.0341 | |||
| Jensen Alpha | 0.1035 | |||
| Total Risk Alpha | (0.40) | |||
| Sortino Ratio | 0.0487 | |||
| Treynor Ratio | 0.144 | |||
| Maximum Drawdown | 39.27 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 8.39 | |||
| Downside Variance | 17.06 | |||
| Semi Variance | 15.44 | |||
| Expected Short fall | (5.22) | |||
| Skewness | 2.29 | |||
| Kurtosis | 10.58 |
MapLight Therapeutics Backtested Returns
MapLight Therapeutics appears to be somewhat reliable, given 3 months investment horizon. MapLight Therapeutics has Sharpe Ratio of 0.0912, which conveys that the firm had a 0.0912 % return per unit of risk over the last 3 months. By analyzing MapLight Therapeutics' technical indicators, you can evaluate if the expected return of 0.56% is justified by implied risk. Please exercise MapLight Therapeutics' Mean Deviation of 4.03, downside deviation of 4.13, and Risk Adjusted Performance of 0.0496 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, MapLight Therapeutics holds a performance score of 7. The company secures a Beta (Market Risk) of 2.05, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MapLight Therapeutics will likely underperform. Please check MapLight Therapeutics' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether MapLight Therapeutics' current price movements will revert.
Auto-correlation | 0.16 |
Very weak predictability
MapLight Therapeutics Common has very weak predictability. Overlapping area represents the amount of predictability between MapLight Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MapLight Therapeutics price movement. The serial correlation of 0.16 indicates that over 16.0% of current MapLight Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | 0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.69 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
MapLight Net Income Per Share
Net Income Per Share |
|
Based on the recorded statements, MapLight Therapeutics Common reported net income of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The net income for all United States stocks is 100.0% higher than that of the company.
MapLight Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MapLight Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MapLight Therapeutics could also be used in its relative valuation, which is a method of valuing MapLight Therapeutics by comparing valuation metrics of similar companies.MapLight Therapeutics is currently under evaluation in net income category among its peers.
About MapLight Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MapLight Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MapLight Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MapLight Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.